Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 study

Autor: John H Strickler, Andrea Cercek, Salvatore Siena, Thierry André, Kimmie Ng, Eric Van Cutsem, Christina Wu, Andrew S Paulson, Joleen M Hubbard, Andrew L Coveler, Christos Fountzilas, Adel Kardosh, Pashtoon M Kasi, Heinz-Josef Lenz, Kristen K Ciombor, Elena Elez, David L Bajor, Chiara Cremolini, Federico Sanchez, Michael Stecher, Wentao Feng, Tanios S Bekaii-Saab, Marc Peeters, Marc Van den Evnde, Christophe Borg, Matthieu Sarabi, Francois Ghiringhelli, Benoist Chibaudel, Maria G. Zampino, Susana R. Keranen, Ramon Salazar, Pilar Alfonso, John H. Strickler, Andrew S. Paulson, Joleen M. Hubbard, Andrew L. Coveler, Pashtoon M. Kasi, Kristen K. Ciombor, David L. Bajor, Tanios S. Bekaii-Saab, Olumide Gbolahan, Patrick Boland, Daniel Berg, Timothy Goggins, Anwar Saeed, Howard Burris, Johanna Bendell, Darryl Outlaw, Isaac Tafur, Ardaman Shergill, Daniel Catenacci, Jun Gong, Ignacio Garrido-Laguna, Gene Finley, Benjamin Weinberg, Anthony Shields, Philip Philip, Anita Turk, Anthony Nguyen, Fadi Braiteh, Vijay Patel, William Harwin, Ian Anderson, Ajay Kundra, Christopher Chen, James Ford, Madappa Kundranda, Danny Nguyen, Suresh Ratnam, Donald Richards, Sujatha Nallapareddy, Sridhar Beeram, Scott McKenney, Spencer Shao

Publikováno v: The Lancet Oncology. 24:496-508

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7adfd2ad44d4d2c2a9c7ef887cf177ac
https://doi.org/10.1016/s1470-2045(23)00150-x

Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?

Autor: Roberto Moretto, Andrew Elliott, Daniele Rossini, Rossana Intini, Veronica Conca, Filippo Pietrantonio, Andrea Sartore-Bianchi, Carlotta Antoniotti, Cosimo Rasola, Mario Scartozzi, Massimiliano Salati, Nicoletta Pella, Maria Alessandra Calegari, Martina Carullo, Francesca Corti, Gianluca Mauri, Matteo Fassan, Gianluca Masi, Pavel Brodskiy, Heinz-Josef Lenz, Anthony Shields, Sara Lonardi, Michael Korn, Chiara Cremolini

Publikováno v: Br J Cancer

BACKGROUND: Recent data suggest that BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients with right-sided tumours and ECOG-PS = 0 may achieve benefit from the triplet regimen differently than those with left-sided tumours and ECOG-PS > 0.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a62e244c05977be4d0680d34a649a6a4
https://doi.org/10.1038/s41416-022-01852-0

Abstract CT241: ENVOY-001: A phase 1, multicenter, open-label study of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in HLA-A*02+ patients with HPV16+ recurrent, locally advanced, or metastatic solid tumors

Autor: Victoria Villaflor, Rajwanth Veluswamy, Elena Garralda, Richard Maziarz, Emese Zsiros, Anthony Shields, Mariano Ponz-Sarvise, Martijn Lolkema, Mehdi Brahmi, Julia Jennings, Nathan Miselis, Lindsay Moore, Katarina Blagovic, Rui-Ru Ji, Scott Loughhead, Ricardo Zwirtes, Sandip Patel

Publikováno v: Cancer Research. 82:CT241-CT241

Background: AAC-HPV consists of autologous RBCs engineered using Cell Squeeze® technology to deliver synthetic long peptides (SLP) of HPV16 E6, E7 and the adjuvant, poly I:C. After intravenous (IV) administration, the AACs are designed to be phagocy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2458005dff367dcc31f3bb2f11036b86
https://doi.org/10.1158/1538-7445.am2022-ct241

Abstract 5315: Anti-tumor activity of KRASG12C inhibitors is enhanced when combined with Cdc42 effector p21-activated kinase 4 targeting agents

Autor: Husain Yar Khan, Sahar Bannoura, Hirva Mamdani, Amro Aboukameel, Yousef Mzannar, Yiwei Li, Mohammad Najeeb Al-Hallak, Ibrahim Azar, Steve Kim, Rafic Beydoun, Ramzi Mohammad, Yosef Landesman, Yue Zhang, Erkan Baloglu, William Senapedis, Ammar Sukari, Misako Nagasaka, Anthony Shields, Asfar S. Azmi

Publikováno v: Cancer Research. 82:5315-5315

Background: KRASG12C inhibitors sotorasib and adagrasib have shown impressive results in clinical studies. These inhibitors efficiently block KRAS downstream effectors such as RAF, MEK, and ERK/p-ERK. However, factors such as feedback reactivation or

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cfe3dbfb192688c2c5de34b29eb0f108
https://doi.org/10.1158/1538-7445.am2022-5315

373 Phase 1/2 study of subcutaneously administered ALKS 4230, a novel engineered cytokine, as monotherapy and in combination with pembrolizumab, in patients with advanced solid tumors: ARTISTRY-2

Autor: John Powderly, Bradley Carthon, Marc Ernstoff, Anthony Olszanski, John Wrangle, Anthony Shields, Sarina Piha-Paul, Kelly Curtis, Ilda Bidollari, Yangchun Du, Lei Sun, Emily Putiri, Yan Wang, Heather Losey, Bruce Dezube, Ulka Vaishampayan

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss Suppl 3 (2020)

Background ALKS 4230 is a novel engineered cytokine designed to selectively bind and activate the intermediate affinity IL-2 receptor. Intravenous (IV) dosing of ALKS 4230 has shown encouraging efficacy and acceptable tolerability, as monotherapy and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::be59d8e703ebaa05caaf1585a113fc8e
https://doaj.org/article/1ad3ff19fadb4798b39071e0dee24631